Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of TAK-007, Cord Blood-Derived CD19 CAR-NK Cells, in Adult Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)

Justin M. Darrah, Indumathy Varadarajan, Amitkumar Mehta, Jennifer N. Saultz, Matthew McKinney, Monalisa Ghosh, Usama Gergis, Girish Bende, Siddha Kasar, Bradley Hupf, Sharon Chen, Leopold Sellner, Reem Karmali

Blood (2024) 144 (Supplement 1): 95.

https://doi.org/10.1182/blood-2024-194807

Published: 2024

Journal Articles

Optimizing Therapeutic Outcome of CD19(T2)28z1XX Chimeric Antigen Receptor (CAR) T in Adult Patients with Large B-Cell Lymphoma through a Quantitative Medicine Approach

Agnish Dey, Jia Li, Jae H. Park, Leopold Sellner, Varsha Sundaresan, Maria Lia Palomba, Jorge Mansilla-Soto, Brigitte Senechal, Xiuyan Wang, Devanjan S Sikder, Ajeeta Dash, Isabelle Riviere, Michel Sadelain, Ganesh Mugundu

Blood (2024) 144 (Supplement 1): 7138.

https://doi.org/10.1182/blood-2024-203375

Published: 2024

Journal Articles

Role of Cell Therapy Product Characteristics in Patient Response to TAK-940 (CD19(T2)28z1xx Chimeric Antigen Receptor (CAR) T): Biomarker Analyses from a Phase I Study in Adult Patients with Relapsed or Refractory B-Cell Malignancies

Varsha Sundaresan, Brigitte Senechal, Xiuyan Wang, Shubhra Kashyap, Erica Tong, Adarsh Joshi, Ajeeta Dash, Leopold Sellner, Sharon Chen, Devin McAvoy, Kinga K Hosszu, Devanjan S Sikder, Isabelle Riviere, Michel Sadelain, Jae H. Park, Reshma Singh

Blood (2023) 142 (Supplement 1): 349.

https://doi.org/10.1182/blood-2023-177712

Published: 2023

Journal Articles

A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Jae H. Park, Maria Lia Palomba, Sean M. Devlin, Yannis K. Valtis, Devanjan S Sikder, Brigitte Senechal, Xiuyan Wang, Elizabeth Cathcart, Kelly Liotta, Alina Yu, Kelsey Stocker, Honglei Zhang, Heiko Schoder, Doris Leithner, Jia Li, Leopold Sellner, Jorge Mansilla-Soto, Isabelle Riviere, Michel Sadelain

Blood (2023) 142 (Supplement 1): 892.

https://doi.org/10.1182/blood-2023-187623

Published: 2023

Journal Articles

A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Jae H Park, M. Lia Palomba, Isabelle Rivière, Devanjan S. Sikder, Brigitte Senechal, Xiuyan Wang, Vladimir P. Bermudez, Elizabeth R. Cathcart, Kelly Liotta, Jannakie Joseph, Jia Li, Yunqi Zhao, Rachael Liu, Sharon Chen, Leopold Sellner, Michel Sadelain

Blood (2022) 140 (Supplement 1): 403–404.

https://doi.org/10.1182/blood-2022-168206

Published: 2022

Journal Articles

Third-Generation Chimeric Antigen Receptor (CAR) T Cells in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin Lymphoma (NHL) - Results from the Heidelberg Trial 1 (HD-CAR-1 trial)

Maria-Luisa Schubert, Anita Schmitt, Brigitte Neuber, Angela Hückelhoven-Krauss, Alexander Kunz, Lei Wang, Birgit Michels, Philip Waldhoff, Leopold Sellner, Felix Korell, Susanne Hofmann, Petra Pavel, Anthony D Ho, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt

Blood (2021) 138 (Supplement 1): 1734.

https://doi.org/10.1182/blood-2021-152028

Published: 2021

Journal Articles

Transcriptional Profiling Reveals Strong Impact of Major Molecular Disease Subgroups and Mixed Epistasis in Chronic Lymphocytic Leukemia

Thorsten Zenz, MD, Almut Luetge, Junyan Lu, PhD, Huellein Jennifer, PhD, Sascha Dietrich, MD, Leopold Sellner, MD, Wolfgang Huber, PhD

Blood (2019) 134 (Supplement_1): 1742.

https://doi.org/10.1182/blood-2019-126388

Published: 2019

Journal Articles

Third-Generation CAR T Cells Targeting CD19 Are Associated with an Excellent Safety Profile and Might Improve Persistence of CAR T Cells in Treated Patients

Maria-Luisa Schubert, MD, Anita Schmitt, MD, Brigitte Neuber, Angela Hückelhoven-Krauss, Alexander Kunz, Lei Wang, MD, Ulrike Gern, Birgit Michels, Leopold Sellner, MD, Susanne Hofmann, MD, Carsten Müller-Tidow, MD, Peter Dreger, Michael Schmitt, MD

Blood (2019) 134 (Supplement_1): 51.

https://doi.org/10.1182/blood-2019-125423

Published: 2019

Journal Articles

No Inhibition of Anti-Viral and Anti-Leukemia Effects By Extracorporeal Photopheresis Therapy

Blood (2018) 132 (Supplement 1): 3399.

https://doi.org/10.1182/blood-2018-99-113277

Published: 2018

Journal Articles

Biomarkers for Clinical Response of Extracorporeal Photopheresis

Blood (2017) 130 (Supplement 1): 3264.

https://doi.org/10.1182/blood.V130.Suppl_1.3264.3264

Published: 2017

Journal Articles

PI3K Inhibition with Idelalisib for Optimized Production of Chimeric Antigen Receptor T Cells

Sophia Stock, Jean-Marc Hoffmann, Lei Wang, MD, Wenjie Gong, Angela Hückelhoven, PhD, Brigitte Neuber, PhD, Maria-Luisa Schubert, MD, Ulrike Gern, Anita Schmitt, MD, Carsten Müller-Tidow, Peter Dreger, MD, Michael Schmitt, MD PhD, Leopold Sellner, MD

Blood (2017) 130 (Supplement 1): 3194.

https://doi.org/10.1182/blood.V130.Suppl_1.3194.3194

Published: 2017

Journal Articles

Marked Impact of Different Cytokines on Phenotype and Cytotoxic Activity of CD19-Specific CAR T Cells

Jean-Marc Hoffmann, Lei Wang, Angela Hückelhoven, PhD, Anita Schmitt, MD, Ulrike Gern, Leopold Sellner, MD, Christian Kleist, PhD, Jessica Wenthe, Patrick Wuchter, MD, Maria-Luisa Schubert, MD, Hyeon Joo Yoo, Ming Ni, Susanne Hofmann, MD, Peter Dreger, MD, Anthony D. Ho, MD, Angelica Loskog, PhD, Michael Schmitt, MD

Blood (2016) 128 (22): 3509.

https://doi.org/10.1182/blood.V128.22.3509.3509

Published: 2016

Journal Articles

T-Prolymphocytic Leukemia Is Sensitive to Polyclonal T Cell-Derived Graft-Versus-Leukemia Effects: Evidence from Minimal Residual Disease Kinetics and TCR Repertoire Diversity Analyses

Leopold Sellner, MD, Peter Dreger, MD, Max Schlitt, Henrik Knecht, Dietrich Herrmann, Thomas Reigl, Adam Krejci, Vojtech Bystry, Nikos Darzentas, Michael Rieger, MD, Sascha Dietrich, MD, Thorsten Zenz, MD, Anthony D. Ho, MD, Michael Kneba, Monika Brueggemann

Blood (2015) 126 (23): 3159.

https://doi.org/10.1182/blood.V126.23.3159.3159

Published: 2015

Journal Articles

Subgroups of T-Cell Prolymphocytic Leukemia (T-PLL) Discovered By High-Throughput Ex Vivo Drug Testing and Genetic Profiling

Emma I Andersson, MSc, Shady Adnan, MD MSc, Leopold Sellner, MD, Dorine Bellanger, Alexandra Schrader, Giuliano Crispatzu, Henan Zhang, MD, Carlos C Mateos, PhD, Edgar Faber, MD PhD, Steffen Koschmieder, MD, Tim H. Brummendorf, MD PhD, Krister Wennerberg, PhD, Wei Ding, MD PhD, Marc-Henri Stern, MD PhD, Marco Herling, MD, Simon Anders, PhD, Wolfgang Huber, PhD, Thorsten Zenz, MD, Satu Mustjoki, MD, PhD

Blood (2015) 126 (23): 315.

https://doi.org/10.1182/blood.V126.23.315.315

Published: 2015

Journal Articles

Discovery of Novel Drug Sensitivities in T-Prolymphocytic Leukemia (T-PLL) By High-Throughput Ex Vivo Drug Testing and Genetic Profiling

Emma I Andersson, MSc, Leopold Sellner, MD, Malgorzata Oles, Tea Pemovska, MSc, Paavo Pietarinen, MSc, Anneli Lauhio, MD, Katarzyna Tomska, Carlos Cuesta-Mateos, MD PhD, Edgar Faber, Tim H. Brummendorf, MD PhD, Olli Kallioniemi, MD PhD, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD, Wolfgang Huber, PhD, Krister Wennerberg, PhD, Thorsten Zenz, MD, Satu Mustjoki, MDPhD

Blood (2014) 124 (21): 917.

https://doi.org/10.1182/blood.V124.21.917.917

Published: 2014

Journal Articles

Understanding CD20 Regulation By Loss-Of-Function RNAi Screen

Mikolaj Slabicki, PhD, Leopold Sellner, MD, Alexander Jethwa, Tatjana Stolz, Srinivas Mamidi, PhD, Michael Boettcher, PhD, Michael Kirschfink, Thorsten Zenz, MD

Blood (2013) 122 (21): 4221.

https://doi.org/10.1182/blood.V122.21.4221.4221

Published: 2013

Journal Articles

Systematic Mapping Of Drug and Pathway Sensitivity In Chronic Lymphocytic Leukemia Identifies Synthetic Lethal Interactions Of Mutant p53

Leopold Sellner, MD, Oles Malgorzata, Mikolaj Slabicki, PhD, Carolin Blume, Hüllein Jennifer, Tatjana Stolz, Martin Sill, PhD, Sascha Dietrich, MD, Olaf Merkel, PhD, Anna Jauch, PhD, Manfred Hensel, MD, Davide Rossi, Zirlik Katja, MD, Martina Seiffert, PhD, Anthony D. Ho, MD, von Kalle Christof, MD, Hanno Glimm, MD, Wolfgang Huber, PhD, Thorsten Zenz, MD

Blood (2013) 122 (21): 173.

https://doi.org/10.1182/blood.V122.21.173.173

Published: 2013

Journal Articles

Autologous Re-Transplantation for Patients with Relapsed Multiple Myeloma: A Single Center Experience with 200 Patients.

Kai Neben, MD, Leopold Sellner, MD, Christiane Heiss, Dipl.Stat, Axel Benner, Dipl.Stat., Marc S Raab, MD, Jens Hillengass, MD, Dirk Hose, MD, PhD, Nicola Lehners, MD, Gerlinde Egerer, MD, Anthony D Ho, MD, Hartmut Goldschmidt, MD, PhD

Blood (2012) 120 (21): 3086.

https://doi.org/10.1182/blood.V120.21.3086.3086

Published: 2012

Journal Articles

Reapplication of High-Dose Chemotherapy with Melphalan Followed by Autologous Hematopoietic Stem Cell Transplantation as Salvage Therapy for Patients with Relapsed Multiple Myeloma

Leopold Sellner, MD, Sonja Teodorov, Christiane Heiss, Axel Benner, Gerlinde Egerer, MD, Peter Dreger, MD, Anthony D. Ho, MD, Hartmut Goldschmidt, MD, Kai Neben, MD

Blood (2010) 116 (21): 3568.

https://doi.org/10.1182/blood.V116.21.3568.3568

Published: 2010

Journal Articles

Gene Therapy of Chronic Myelogenous Leukemia Using Pseudotyped Recombinant Adeno-Associated Viral Vectors.

Leopold Sellner, MD, Marlon R Veldwijk, PhD, Jürgen A. Kleinschmidt, PhD, Stephanie Laufs, PhD, Julian Topaly, MD, W. Jens Zeller, MD, Frederik Wenz, MD, Stefan Fruehauf, MD

Blood (2009) 114 (22): 4506.

https://doi.org/10.1182/blood.V114.22.4506.4506

Published: 2009

NARROW

Efficacy and Safety of TAK-007, Cord Blood-Derived CD19 CAR-NK Cells, in Adult Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)

Optimizing Therapeutic Outcome of CD19(T2)28z1XX Chimeric Antigen Receptor (CAR) T in Adult Patients with Large B-Cell Lymphoma through a Quantitative Medicine Approach

Role of Cell Therapy Product Characteristics in Patient Response to TAK-940 (CD19(T2)28z1xx Chimeric Antigen Receptor (CAR) T): Biomarker Analyses from a Phase I Study in Adult Patients with Relapsed or Refractory B-Cell Malignancies

A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Third-Generation Chimeric Antigen Receptor (CAR) T Cells in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin Lymphoma (NHL) - Results from the Heidelberg Trial 1 (HD-CAR-1 trial)

Transcriptional Profiling Reveals Strong Impact of Major Molecular Disease Subgroups and Mixed Epistasis in Chronic Lymphocytic Leukemia

Third-Generation CAR T Cells Targeting CD19 Are Associated with an Excellent Safety Profile and Might Improve Persistence of CAR T Cells in Treated Patients

No Inhibition of Anti-Viral and Anti-Leukemia Effects By Extracorporeal Photopheresis Therapy

Biomarkers for Clinical Response of Extracorporeal Photopheresis

PI3K Inhibition with Idelalisib for Optimized Production of Chimeric Antigen Receptor T Cells

Marked Impact of Different Cytokines on Phenotype and Cytotoxic Activity of CD19-Specific CAR T Cells

T-Prolymphocytic Leukemia Is Sensitive to Polyclonal T Cell-Derived Graft-Versus-Leukemia Effects: Evidence from Minimal Residual Disease Kinetics and TCR Repertoire Diversity Analyses

Subgroups of T-Cell Prolymphocytic Leukemia (T-PLL) Discovered By High-Throughput Ex Vivo Drug Testing and Genetic Profiling

Discovery of Novel Drug Sensitivities in T-Prolymphocytic Leukemia (T-PLL) By High-Throughput Ex Vivo Drug Testing and Genetic Profiling

Understanding CD20 Regulation By Loss-Of-Function RNAi Screen

Systematic Mapping Of Drug and Pathway Sensitivity In Chronic Lymphocytic Leukemia Identifies Synthetic Lethal Interactions Of Mutant p53

Autologous Re-Transplantation for Patients with Relapsed Multiple Myeloma: A Single Center Experience with 200 Patients.

Reapplication of High-Dose Chemotherapy with Melphalan Followed by Autologous Hematopoietic Stem Cell Transplantation as Salvage Therapy for Patients with Relapsed Multiple Myeloma

Gene Therapy of Chronic Myelogenous Leukemia Using Pseudotyped Recombinant Adeno-Associated Viral Vectors.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only